VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
SOPH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
SOPHSOPHiA GENETICS S.A.
$5.75$412M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksSOPHBalance Sheet

SOPHiA GENETICS S.A. (SOPH) Balance Sheet

7Y historyFree accessUpdated daily

Financial stability has deteriorated significantly, with the debt-to-equity ratio surging to 1.37 in 2026Q1 from 0.12 in 2023Q4, reflecting an increasing reliance on leverage.

SOPH Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Total Current Assets95.81M99.08M99.41M148.05M196.25M282.86M109.69M33.76M
Cash & Short-Term Investments65.39M70.29M80.23M123.25M178.61M265.32M97.34M18.43M
Cash Only65.39M70.29M80.23M123.25M161.31M192.96M74.63M18.07M
Short-Term Investments000017.31M72.36M22.72M366K
Accounts Receivable14.31M18.53M8.69M15.21M8.05M7.09M7.85M9.71M
Days Sales Outstanding57.187.5148.6788.9861.863.97100.94139.67
Inventory7.09M6.35M5.87M6.48M5.16M5.73M3.38M3.61M
Days Inventory Outstanding90.4778.69100.86121.59115.41137.31115.34174.94
Other Current Assets9.02M758K835K345K731K775K27K339K
Total Non-Current Assets61.18M64.38M55.9M58.11M47.58M37.32M22.42M17.9M
Property, Plant & Equipment16.8M18.05M19.38M23.1M21.4M15.96M5.54M6.45M
Fixed Asset Turnover4.58x4.28x3.36x2.70x2.22x2.54x5.13x3.93x
Goodwill35.82M9.56M8.34M9M8.19M8.3M8.6M7.83M
Intangible Assets026.34M20.66M18.19M11.78M7.38M4.68M2.4M
Long-Term Investments1.98M1.98M0000775K373K
Other Non-Current Assets6.75M6.21M5.76M6.1M4.28M3.7M711K839K
Total Assets157M163.46M155.31M206.16M243.84M320.17M132.12M51.66M
Asset Turnover0.49x0.47x0.42x0.30x0.20x0.13x0.21x0.49x
Asset Growth %2.36%5.24%-24.66%-15.45%-23.84%142.34%155.76%-
Total Current Liabilities46.59M50.53M26.8M35.62M26.81M28.6M21.59M19.26M
Accounts Payable12.67M5.32M1.93M2.26M2.17M2.34M1.28M1.73M
Days Payables Outstanding121.6765.8633.2142.3248.5756.0143.6683.79
Short-Term Debt2.71M2.7M00002.87M2.23M
Deferred Revenue (Current)42.31M16.72M5.73M9.49M3.43M4.07M2.64M2.1M
Other Current Liabilities15.27M5.32M11.22M13.58M10.27M9.16M5.25M5.73M
Current Ratio2.06x1.96x3.71x4.16x7.32x9.89x5.08x1.75x
Quick Ratio1.90x1.84x3.49x3.97x7.13x9.69x4.92x1.57x
Cash Conversion Cycle25.9100.35116.32168.25128.64145.26172.62230.82
Total Non-Current Liabilities64.71M65.78M32.02M19.09M16.9M16.17M10.02M10.14M
Long-Term Debt47.84M47.73M13.24M000457K1.61M
Capital Lease Obligations51.5M12.59M14.6M15.67M14.05M11.25M2.88M3.66M
Deferred Tax Liabilities424K424K000000
Other Non-Current Liabilities5M5.04M4.18M3.42M2.85M4.92M6.54M4.79M
Total Liabilities111.31M116.31M58.82M54.71M43.71M44.77M31.61M29.4M
Total Debt62.42M63.02M30.03M18.6M16.74M13.06M7.25M8.46M
Net Debt-2.97M-7.27M-50.2M-104.65M-144.56M-179.9M-67.38M-9.61M
Debt / Equity1.37x1.34x0.31x0.12x0.08x0.05x0.07x0.38x
Debt / EBITDA-0.99x-------
Net Debt / EBITDA0.05x-------
Interest Coverage-15.13x-15.57x-31.03x-132.49x-136.07x-110.71x-48.08x-33.46x
Total Equity45.69M47.15M96.49M151.44M200.13M275.4M100.51M22.25M
Equity Growth %-181.16%-51.14%-36.29%-24.33%-27.33%174%351.67%-
Book Value per Share0.640.701.472.343.124.982.090.35
Total Shareholders' Equity45.69M47.15M96.49M151.44M200.13M275.4M100.51M22.25M
Common Stock4.81M4.81M4.19M4.05M3.46M3.33M2.46M1.95M
Retained Earnings-538.6M-519.28M-440.28M-377.78M-298.8M-211.35M-137.68M-98.34M
Treasury Stock-1.01M-1.22M-702K-646K-117K000
Accumulated OCI92.06M89.15M61.04M53.98M23.96M12.54M8.3M-581K
Minority Interest00000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Insufficient liquidity for operations

Capital Erosion Weakens Financial Foundation

As reported in recent financial statements, SOPH's equity base has contracted from $151.4M in 2023Q4 to $45.7M in 2026Q1, reflecting a persistent trend of capital erosion driven by cumulative losses that significantly impair the company's long-term balance sheet stability and overall financial health.

The consistent decline in equity, coupled with a widening deficit in retained earnings, suggests that the company is struggling to reach a self-sustaining scale. Investors should monitor whether this trajectory necessitates further dilutive financing to maintain operations, as the current pace of capital consumption appears unsustainable.

Leverage Escalation Increases Financial Risk

Based on the provided balance sheet data, SOPH's debt-to-equity ratio has surged from 0.12 in 2023Q4 to 1.37 in 2026Q1, indicating that the firm is increasingly relying on debt financing to bridge the gap between its operating cash burn and its strategic growth objectives.

This rapid shift toward higher leverage in a loss-making environment suggests a heightened risk profile, particularly if the company fails to generate positive cash flow to service these obligations. The reliance on debt to fund operations may limit future financial flexibility and increase sensitivity to interest rate fluctuations.

Liquidity Buffer Nearing Critical Threshold

According to recent SEC filings, SOPH's cash position has declined to $65.4M as of 2026Q1, which, when measured against the company's ongoing operating losses, suggests a tightening liquidity buffer that warrants close investigation regarding the firm's ability to fund its near-term operational requirements.

While the current ratio of 2.06 appears superficially adequate, the underlying cash burn rate indicates that the company's runway is rapidly diminishing. This liquidity profile suggests that management may face significant pressure to secure additional capital or drastically reduce expenditures to avoid a potential funding shortfall.

Goodwill Volatility Masks Asset Quality

As evidenced by the quarterly balance sheet data, SOPH's goodwill has fluctuated significantly, jumping from $9.6M in 2025Q4 to $35.8M in 2026Q1, which may indicate recent acquisition activity that potentially obscures the underlying quality and tangible value of the company's asset base.

The sudden increase in intangible assets warrants further investigation, as it may suggest that the company is attempting to bolster its asset side through inorganic growth rather than organic platform expansion. Investors should be cautious, as such volatility in goodwill can often precede impairment risks if the acquired assets fail to deliver expected synergies.

SOPH — Frequently Asked Questions

Quick answers to the most common questions about buying SOPH stock.

What are the total assets of SOPHiA GENETICS S.A. (SOPH)?

As of 2025, SOPHiA GENETICS S.A. (SOPH) had total assets of $163.5M including $99.1M in current assets.

How much debt does SOPHiA GENETICS S.A. (SOPH) have?

SOPHiA GENETICS S.A. (SOPH) carries total debt of $63.0M, offset by $70.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of SOPHiA GENETICS S.A.?

SOPHiA GENETICS S.A. (SOPH) has total shareholders' equity (book value) of $47.1M ($0.70 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is SOPHiA GENETICS S.A.'s current ratio and liquidity?

SOPHiA GENETICS S.A. (SOPH) reported a current ratio of 1.96x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.